As it is integral in the development of skin melanocyte, gp100 was identified to be a melanocyte differentiation antigen by Bakker et al. in 1994, where the team postulated the potential of the melanocyte lineage-specific antigen to serve as a key target against melanoma [108]. This evidence concerns the gene PMEL and melanoma.